MIRVETUXIMAB SORAVTANSINE
UNII 98DE7VN88D

Substance Identification & Data

This profile provides standardized clinical and technical data for Mirvetuximab Soravtansine, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 98DE7VN88D.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 1453084-37-1 and the RxNorm Concept ID (RxCUI) 2621548. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

98DE7VN88D

CAS Registry Number

1453084-37-1

RxNorm Concept ID

2621548

Detailed Substance Profile

Preferred Name

MIRVETUXIMAB SORAVTANSINE

Official standardized name for this substance within the FDA UNII nomenclature system.

Molecular Formula

98DE7VN88D

The specific atomic composition represented as a molecular structure string.

NCI Thesaurus

C102566

National Cancer Institute reference terminology for clinical and research data.

PubChem CID

91810695

Unique identification number in the NCBI database of chemical substances.

INN ID

10176

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

BC-78

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Mirvetuximab Soravtansine. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

MIRVETUXIMAB SORAVTANSINE

MIRVETUXIMAB SORAVTANSINE-GYNX

Common Names & Synonyms

IMMUNOGLOBULIN G1, ANTI-(HUMAN FOLATE RECEPTOR .ALPHA.) (HUMAN-MUS MUSCULUS MONOCLONAL M9346A HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL M9346A LIGHT CHAIN, DIMER, TETRAAMIDE WITH N2'-(4-((3-CARBOXY-3- SULFOPROPYL)DITHIO)-4-METHYL-1-OXOPENTYL)-N2'-DEACETYLMAYTANSINE

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HUMAN FOLATE RECEPTOR ALPHA (ADULT FOLATEBENDING PROTEIN, FOLATE RECEPTOR 1, KB CELLS FBP, OVARIAN TUMOR-ASSOCIATED ANTIGEN MOV18)); HUMANIZED MOUSE MONOCLONAL ANTIBODY LINKED TO AN AVERAGE OF FOUR MOLECULES OF MAYTANSINE ACID DERIVATIVE : AMIDE BETWEEN AN AVERAGE OF FOUR MOLECULES OF (2RS,12S)-14-((1S,2R,3S,5S,6S,16E,18E,20R,21S)-11- CHLORO-21-HYDROXY-12,20-DIMETHOXY-2,5,9,16-TETRAMETHYL-8,23-DIOXO-4,24- DIOXA-9,22-DIAZATETRACYCLO(19.3.1.110.14.03.5)HEXACOSA-10,12,14(26),16,18- PENTAEN-6-YL)-7,7,11,12-TETRAMETHYL-10,13-DIOXO-2-SULFONYL-14-OXA-5,6-DITHIA11-AZATETRADECANOIC ACID AND AN AVERAGE OF FOUR AMINO GROUPS OF .GAMMA.1 HEAVY CHAIN (1-447) (MUS MUSCULUS VH (IGHV1-37*01-(IGHD)-IGHJ4*01) (88%) (8.8.11) (1-119) -DES-(CH3K107 (448))-IGHG1*01 (119-447)) (221-218')- DISULFIDE WITH KAPPA LIGHT CHAIN (1'-218') (MUS MUSCULUS V-KAPPA (IGKV3-9*01-IGKJ1*02) (81%) (10.3.9) (1'-111') -IGKC*01 (112'-218')) DIMER (227-227'':230-230'')-BISDISULFIDE

MIRVETUXIMAB SORAVTANSINE [INN]

MIRVETUXIMAB SORAVTANSINE [USAN]

MIRVETUXIMAB SORAVTANSINE [WHO-DD]

MIRVETUXIMAB SORAVTANSINE GYNX [WHO-DD]